Changes in frequency of HIV-1-specific cytotoxic T cell precursors and circulating effectors after combination antiretroviral therapy in children

J Infect Dis. 1999 Aug;180(2):359-68. doi: 10.1086/314867.

Abstract

Combination antiretroviral therapy has had a major role in reducing human immunodeficiency virus type 1 (HIV-1) plasma viral loads in HIV-1-infected adults but a variable effect in infants, in whom complete viral suppression appears to be less readily achieved. In adults, after the reduction in plasma viremia, there is a decrease in the numbers of circulating cytotoxic T cell (CTL) effectors and precursors in the majority of patients. This longitudinal study assessed the effect of combination drug therapy on the frequency of HIV-1-specific CTL responses in 8 HIV-1-infected children. Following treatment, the frequency of HIV-1-specific CTL responses initially increased, especially in children with incomplete viral suppression but with increasing CD4+ cell counts. In children with complete viral suppression, the frequency of HIV-1-specific CTL responses decreased, suggesting that viral replication is required to maintain CTL responses in the systemic circulation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Cytotoxicity Tests, Immunologic
  • Drug Therapy, Combination
  • Gene Products, nef / immunology
  • HIV Infections / drug therapy*
  • HIV Infections / immunology*
  • HIV Infections / virology
  • HIV-1 / immunology*
  • HIV-1 / physiology
  • HLA-B8 Antigen / immunology
  • Histocompatibility Antigens Class I / classification
  • Humans
  • Infant
  • Leukocytes, Mononuclear / immunology
  • Leukocytes, Mononuclear / virology
  • Longitudinal Studies
  • Peptide Fragments / immunology
  • RNA, Viral / blood
  • T-Lymphocytes, Cytotoxic / immunology*
  • T-Lymphocytes, Cytotoxic / physiology
  • Viral Load
  • Viremia / drug therapy
  • Viremia / virology
  • nef Gene Products, Human Immunodeficiency Virus

Substances

  • Anti-HIV Agents
  • Gene Products, nef
  • HLA-B8 Antigen
  • Histocompatibility Antigens Class I
  • Peptide Fragments
  • RNA, Viral
  • nef Gene Products, Human Immunodeficiency Virus